Tom 5, Nr 3-4 (2024)
OPINIA EKSPERTÓW
Opublikowany online: 2025-01-20
Wyświetlenia strony
26
Wyświetlenia/pobrania artykułu
6
Zalecenia polskich ekspertów na 2024 rok dotyczące koadministracji szczepionek osobom dorosłym w profilaktyce zakażeń układu oddechowego
DOI: 10.5603/pp.102788
Pneum Pol 2024;5(3-4):123-129.
Streszczenie
Liczne rekomendacje krajowe i międzynarodowe, w tym Światowej Organizacji Zdrowia (WHO, Strategic Advisory Group
of Experts on Immunization, SAGE), europejskie (European Centre for Disease Prevention and Control, ECDC), amerykańskie (Advisory
Committee on Immunization Practices, ACIP), brytyjskie (National Health Service, NHS), kanadyjskie (Public Health Agency
of Canada, PHAC), niemieckie (Ständige Impfkommission, STIKO), francuskie (Haute Autorité de Santé, HAS), szwajcarskie (Federal
Office of Public Health, FOPH), australijskie (Australian Technical Advisory Group on Immunisation, ATAGI) i japońskie (Ministry
of Health, Labour and Welfare, MHLW) jednoznacznie wskazują, że podawanie kilku szczepionek na jednej wizycie jest bezpieczne
i skuteczne. Pomimo braku badań klinicznych obejmujących wszystkie możliwe kombinacje szczepionek, panuje zgodna opinia,
że koadministracja jest znacznie korzystniejsza dla pacjenta niż opóźnienie realizacji programu szczepień.
Słowa kluczowe: zapobieganie zakażeniomczynne uodpornienie
Referencje
- Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009; 27(3): 446–453.
- Severance R, Schwartz H, Dagan R, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU). Hum Vaccin Immunother. 2022; 18(1): 1–14.
- Thompson AR, Klein NP, Downey HJ, et al. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. Hum Vaccin Immunother. 2019; 15(2): 444–451.
- Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine. 2001; 19(32): 4710–4719.
- Won H, Kim JAh, Jeong NY, et al. Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly. Vaccine. 2024; 42(13): 3190–3196.
- Toback S, Galiza E, Cosgrove C, et al. 2019nCoV-302 Study Group. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022; 10(2): 167–179.
- Ofori-Anyinam O, Leroux-Roels G, Drame M, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine. 2017; 35(46): 6321–6328.
- Wagenhäuser I, Reusch J, Gabel A, et al. Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination. Eur Respir J. 2023; 61(1).
- Naficy A, Kuxhausen A, Seifert H, et al. No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial. Clin Infect Dis. 2023; 77(9): 1238–1246.
- Janssen C, Mosnier A, Gavazzi G, et al. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies. Hum Vaccin Immunother. 2022; 18(6): 2131166.
- Moro PL, Zhang B, Ennulat C, et al. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022. Vaccine. 2023; 41(11): 1859–1863.
- Ali SO, Dessart C, Parikh R. Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview. Vaccine. 2024; 42(8): 2026–2035.
- Barouch SE, Chicz TM, Blanc R, et al. Concurrent administration of COVID-19 and influenza vaccines enhances Spike-specific antibody responses. Open Forum Infect Dis. 2024; 11(4): ofae144.
- Widagdo W, Bastian AR, Jastorff AM, et al. Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial. J Infect Dis. 2024; 230(2): e374–e383.
- Song JY, Cheong HJ, Tsai TF, et al. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine. 2015; 33(36): 4647–4652.
- Severance R, Schwartz H, Dagan R, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU). Hum Vaccin Immunother. 2022; 18(1): 1–14.
- McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine. 2007; 25(17): 3464–3474.
- Tsai IJ, Chang MH, Chen HL, et al. Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults. Vaccine. 2000; 19(4-5): 437–441.
- Jong EC, Kaplan KM, Eves KA, et al. An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. J Travel Med. 2002; 9(2): 66–70.
- Bonanni P, Steffen R, Schelling J, et al. Vaccine co-administration in adults: An effective way to improve vaccination coverage. Hum Vaccin Immunother. 2023; 19(1): 2195786.
- Achterbergh RCA, McGovern I, Haag M. Co-Administration of Influenza and COVID-19 Vaccines: Policy Review and Vaccination Coverage Trends in the European Union, UK, US, and Canada between 2019 and 2023. Vaccines (Basel). 2024; 12(2).
- CDC Timing and Spacing of Immunobiologics General Best Practice Guidelines for Immunization. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (31.10.2024).
- King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J. 1994; 13(5): 394–407.
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. https://www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm (31.10.2024).
- ECDC. COVID-19 vaccine tracker. 2021. https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab. (07.12.2021).
- CDC Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability (31.10.2024).
- Lazarus R, Baos S, Cappel-Porter H, et al. ComfluCOV Trial Group. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021; 398(10318): 2277–2287.
- Immunize.org Vaccinating Adults: A Step-by-Step Guide (2017). https://www.immunize.org/wp-content/uploads/guide/pdfs/vacc-adults-entire.pdf (31.10.2024).
- National Centre for Immunisation Research and Surveillance (NCIRS) Co-administration of vaccines for adults: a guide for immunisation providers. https://ncirs.org.au/sites/default/files/2022-08/Co-administration%20of%20vaccine%20guide%20for%20Adullts_3%20Aug%202022_final.pdf (31.10.2024).
- Program Szczepień Ochronnych na rok 2024. https://www.gov.pl/attachment/36eb4432-a90d-40f0-93e3-fda3907e9373 (31.10.2024).
- Bonanni P, Boccalini S, Bechini A, et al. Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines. Hum Vaccin Immunother. 2020; 16(6): 1313–1321.
- Kenigsberg TA, Goddard K, Hanson KE, et al. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023; 41(39): 5678–5682.
- Broderick MP, Romero-Steiner S, Rajam G, et al. Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone. Clin Vaccine Immunol. 2016; 23(8): 672–680.
- Alberer M, Burchard G, Jelinek T, et al. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study. Travel Med Infect Dis. 2014; 12(5): 485–493.
- Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J. 2011; 30(12): e225–e234.
- Rinderknecht S, Michaels MG, Blatter M, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011; 30(10): e179–e185.
- Eurostat. Population structure and ageing. 2021. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing#Slightly_more_than_three_persons_of_working_age_for_every_person_aged_65_or_over (07.12.2021).
- Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023; 72(3): 1–39.
